Peripheral Immunotype Correlates with Minimal Residual Disease Status and is Modulated by Immunomodulatory Drugs (IMiDs) in Multiple Myeloma.Biol Blood Marrow Transplant.(2018).
Summary of the Second Annual BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling.Biol Blood Marrow Transplant.(2018).
A Review of Growth Factor Support in Bloodless Autologous Hematopoietic Stem-cell Transplant.Biol Blood Marrow Transplant.(2019).